It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).
It is very uncertain whether IV iron isomaltoside changes serious adverse events ‐ remission or mild disease (8 weeks) compared with oral iron sulphate (very low certainty).
It is very uncertain whether IV iron sucrose changes serious adverse events ‐ mild to moderate disease (20 weeks) compared with oral iron sulphate (very low certainty).
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (12 weeks) compared with IV iron sucrose (very low certainty).
It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
It is very uncertain whether oral ferric maltol changes serious adverse events (12 weeks) compared with IV ferric carboxymaltose (very low certainty).